EMHTF - Emerald Health Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.2176
-0.0074 (-3.29%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.2250
Open0.2162
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2100 - 0.2297
52 Week Range0.2100 - 3.4900
Volume394,020
Avg. Volume352,290
Market Cap34M
Beta (3Y Monthly)1.95
PE Ratio (TTM)N/A
EPS (TTM)-0.1290
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Emerald Health Therapeutics Reports Third Quarter 2019 Financial Results; Sales Double Third Quarter in a Row

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) reported financial results for the quarter and nine-month period ended September 30, 2019. Full versions of the Company’s unaudited condensed, interim consolidated financial statements and MD&A can be found on SEDAR at www.sedar.com. Net loss of $17.5M impacted by $2.8M inventory write down and decrease of $9.1M in fair value adjustments of biological assets.

  • GlobeNewswire

    Emerald Health Therapeutics Closes $2.5 Million Prospectus Sale and Concurrent Secondary Sale

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF), announced today that it closed its prospectus sale (the "Offering") to a single Canadian institutional accredited investor (the “Investor”), as announced on November 13, 2019. Each Unit consists of one common share of Emerald (each, a "Common Share") and one common share purchase warrant (each, a "Warrant").

  • GlobeNewswire

    Emerald Health Therapeutics Maintains 50% Share Ownership in Pure Sunfarms

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today responded to misleading public disclosure made by Village Farms International, Inc. ("Village Farms") (TSX: VFF; Nasdaq: VFF) yesterday in connection with their joint venture, Pure Sunfarms Corp. ("PSF"). Emerald reiterates the disclosure in its November 20, 2019, news release and confirms that, factually, Emerald and Village Farms each continue to own 50% of PSF. As set out in Village Farms’ own news release, no additional shares of PSF have been issued to Village Farms and none of Emerald’s escrowed shares in PSF have been cancelled.

  • GlobeNewswire

    Emerald Health Therapeutics’ Pure Sunfarms Joint Venture to Supply Cannabis Products to Alberta

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) announced that its 50%-owned joint venture for large-scale, low-cost, quality cannabis production, Pure Sunfarms Corp. (“Pure Sunfarms” or “PSF”), has secured a cannabis supply agreement with Alberta Gaming, Liquor & Cannabis (AGLC), to become an official supplier of recreational adult-use cannabis products to the province’s licensed private sector retailers including Alberta’s only legal online source for recreational cannabis (AlbertaCannabis.org). The AGLC is the wholesaler to private retailers and the only authorized online retailer in Alberta.

  • GlobeNewswire

    Emerald Health Therapeutics Completing Planting in Recently Fully-Licensed, Wholly-Owned Growing Facilities

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has completed planting at its indoor Québec facility, Verdélite, and expects to complete planting in the next days in the first of its two greenhouses in Metro Vancouver, allowing for transition into the commercial phase of these operations and a significant increase in quality cannabis production with approximately 7,500kg of product output targeted for these facilities in 2020. The growing area is equipped to produce 4,800 kg of high-quality craft cannabis annually, and Verdélite’s established packaging and processing lines are built to process the targeted production volume and a wide diversity of value-added products.

  • Market Exclusive

    Village Farms Eyes Increased Position in Pure Sunfarms

    Following an equity payment default by Emerald Health Therapeutics (OTCQB: EMHTF) under the Delta 2 option agreement involving Pure Sunfarms, Village Farms International (TSX: VFF) (NASDAQ: VFF) has informed Pure Sunfarms of exercising its rights to increase its ownership in Pure Sunfarms and advanced an equity payment to Pure Sunfarms of $5.94 million. Emerald was obligated to […]The post Village Farms Eyes Increased Position in Pure Sunfarms appeared first on Market Exclusive.

  • GlobeNewswire

    Emerald Health Therapeutics Responds to Inaccurate Allegations by Village Farms

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today responded to inaccurate allegations made by Village Farms International, Inc. ("Village Farms") (TSX: VFF; Nasdaq: VFF) in connection with their 50/50 joint venture, Pure Sunfarms Corp. ("PSF"), and updated the market on certain related matters. Late yesterday evening Emerald received notice from Village Farms stating that Village Farms had advanced $5.94 million to PSF for additional equity. Village Farms claims that it has the right to acquire these shares under the PSF shareholders’ agreement.

  • GlobeNewswire

    Emerald Health Therapeutics’ Pure Sunfarms JV Records Q3 Net Sales of $24.0 Million, 69% Gross Margin, 56% EBITDA Margin, Fourth Consecutive Quarter of Positive EBITDA, and $0.63/gram All-in Production Cost

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has provided preliminary, unaudited financial results for the third quarter of 2019 for its BC-based, 50%-owned joint venture, Pure Sunfarms (“PSF”). The Company will report complete financial results for the third quarter ended September 30, 2019, after market close on Friday, November 29, 2019, and host its third quarter 2019 financial results conference call on Monday, December 2, 2019 at 10:30 a.m. ET. Sales for the third quarter consisted entirely of dried flower sold primarily to other licensed producers.

  • GlobeNewswire

    Emerald Health Therapeutics Announces $2.5 Million Prospectus Sale and Concurrent Secondary Sale

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF), has entered into a binding term sheet with a single Canadian institutional accredited investor (the “Investor”) under which the Investor has agreed, subject to certain customary conditions, to purchase 4,385,965 units of Emerald (each, a "Unit") at a price of $0.57 per Unit for total gross proceeds of $2,500,000 (the "Offering"). Each Unit will consist of one common share of Emerald (each, a "Common Share") and one common share purchase warrant (each, a "Warrant").

  • GlobeNewswire

    Emerald Health Therapeutics Receives Organic Certification for Greenhouse and Outdoor Metro Vancouver Operation

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has received organic certification for cannabis production at its Metro Vancouver operation in British Columbia, which encompasses 156,000 square feet in two greenhouses as well as 12 acres (~500,000 square feet) of licensed outdoor cultivation area.

  • InvestorPlace

    10 Medical Marijuana Stocks to Cure Your Portfolio

    [Editor's note: "10 Medical Marijuana Stocks to Cure Your Portfolio" was previously published in October 2019. It has since been updated to include the most relevant information available.] Invariably, no other investment class generates as much interest and controversy as marijuana stocks. Within a generation, public sentiment toward legalization shifted dramatically from strongly opposed to mostly supportive. This is largely due to demographics, as the more progressive millennials replace older Americans in positions of influence.Additionally, marijuana stocks represent a viable economic channel that can help bridge the gap for many states' financial issues. For instance, green-friendly Colorado enjoys significant tax revenues from its botanical industry. I don't see this trend changing for the worse anytime soon, as awareness and popularity is only increasing.InvestorPlace - Stock Market News, Stock Advice & Trading TipsOf course, cannabis isn't without its controversies. Primarily, the federal government classifies marijuana as a Schedule I drug, putting it on par with hardcore narcotics like cocaine. Thus, no matter how liberal some states become toward their agricultural ambitions, the specter of federal oversight and crackdowns keeps many entrepreneurs and businesses away.However, we have one critical exception to the rule: marijuana stocks that specialize in medicinal and therapeutic benefits. For one thing, medical cannabis mitigates the stereotypical image of potheads and general no-gooders. Plus, people experiment with pharmaceuticals all the time. Why not allow these same patients the choice for natural alternatives? * 7 Retail Stocks to Avoid for the Holidays More critically for marijuana stocks, the medicinal aspect offers the best chance for international acceptance. Currently, very few jurisdictions allow recreational weed. Given the abundance of traditional and conservative nations, a green world is unlikely. But as Thailand and South Korea demonstrated, medical cannabis is a much easier sell.As a result, you want exposure not just to marijuana stocks, but also to the therapeutic element. Here are 10 names to consider: AbbVie (ABBV)Source: Shutterstock Whenever you have a discussion about cannabis stocks, chances are, AbbVie (NYSE:ABBV) isn't the first name you think about. One of the healthcare sector's blue chips, ABBV stock has soared on its vast therapeutic pipeline.We're talking mainstream solutions for common ailments and diseases like arthritis and plaque psoriasis.Still, AbbVie maintains some botanical credibility with its Marinol therapy. A synthetic cannabis-based drug, Marinol addresses chemotherapy-related side effects, such as vomiting or nausea. In addition, it helps restore appetite among AIDS patients.Of course, you should note that Marinol isn't among AbbVie's top-selling products. Therefore, you're only getting limited exposure to cannabis with ABBV stock. But based on the extreme volatility of marijuana stocks, that isn't such a bad gig. Emerald Health Therapeutics (EMHTF)Source: Shutterstock Not that I would know, but growing cannabis allegedly isn't rocket science.With the right conditions, the right equipment and a reasonable car, anyone can grow their stash. But cultivating the plant so that it addresses specific ailments and symptoms? That takes real effort, which is where Emerald Health Therapeutics (OTCMKTS:EMHTF) comes in.Rather than just pumping out the green stuff, Emerald deliberately seeks out the strains most effective in addressing patients' needs. The company provides a wide selection of strains, which range in weight, tetrahydrocannabinol (THC) content, and cannabidiol (CBD) strength. Their impressive portfolio should lift EMHTF stock over the long run, as interest in CBD products accelerates. * 7 Retail Stocks to Avoid for the Holidays It's important to be careful with pot stocks, though. On a year-to-date basis, EMHTF stock is down 75%. While all cannabis stocks suffer volatility risk, Emerald's concentration on medicinal weed should help mitigate downside pressure. Aurora Cannabis (ACB)Source: Shutterstock I've spent a lot of time discussing Aurora Cannabis (NYSE:ACB), and I don't mean to keep double-dipping into this company. Still, I keep going back for a reason: ACB stock is an excellent play within the medical-marijuana market.A key factor in my bullishness for Aurora is its management team. In my view, they're making smart decisions through their acquisitive strategy.Rather than merely focusing on outright capacity, they're looking out over the horizon. Aurora's buyout of Whistler Medical Marijuana gave the organization significant leverage in medical cannabis due to Whistler's extensive genetics bank.Furthermore, ACB stock is a strong performer. In the beginning of the year, shares skyrocketed roughly 70% before plummeting. It's down 28% this year. The inevitable correction should be only temporary. Among marijuana stocks, Aurora is exceptionally well-positioned for sustainable growth. Cronos Group (CRON)Source: Shutterstock One of the top names among major marijuana stocks, Cronos Group (NASDAQ:CRON) naturally attracts a lot of attention. This time, though, they're attracting the wrong kind.Prior to its earnings report for the second quarter, I worried about the company's revenue target.Hit or exceed it, and management can stave off criticism, but speculators looking for a discounted price may want to put CRON stock back on their radar. After concerns about vaping safety hit the news, Cronos has shed all of this year's gains and more, as it's down nearly 24% YTD. * 7 Retail Stocks to Avoid for the Holidays Plus, Cronos has international legitimacy among medicinally focused cannabis stocks. Featuring partnerships and joint ventures across five continents, the company is ahead of the game. CannTrust (CTST)In business, even the green kind, you can't get ahead of yourself. So while lucrative opportunities exist in the international sector, CannTrust (NYSE:CTST) remains firmly committed to winning its native Canadian market.At the same time, CannTrust can't afford to ignore the rest of the world. Although Canada becoming the first G7 nation to legalize recreational weed generated headlines, our northern neighbors alone can't support this burgeoning industry.Therefore, management has focused on the growth and capacity narrative to compete effectively at home and, later, abroad.To achieve the second leg of this journey, CannTrust teamed up with Denmark's Stenocare to distribute medical cannabis products in that country.It also inked a partnership with an Australian firm for similar distribution arrangements. While it's not the most common name among marijuana stocks, CTST stock provides a risky, but viable, opportunity. Innovative Industrial Properties (IIPR)Most marijuana stocks focus on the industry's front face; namely, production. As I mentioned earlier, marijuana isn't that difficult to grow. So long as you have the green light legally, the physical barrier to entry is relatively short.But the real challenge, though, is finding a consistent source of financing. This is where Innovative Industrial Properties (NYSE:IIPR) lends a helping hand.Despite momentum toward legalization, several financial institutions shy away from cannabis ventures.Innovative Industrial plugs the gap, offering critical capital through its leaseback business model. * 7 Retail Stocks to Avoid for the Holidays Thanks to the company's tremendous utility, IIPR stock has lit up the markets. Shares are currently up more than 75% YTD. Technically, IIPR may have gotten a bit overheated. That said, I wouldn't get too greedy looking for the perfect entry point. Innovative Industrial levers a proven business model that is only increasing in relevancy. Terra Tech (TRTC)Everyone recognizes cannabis stocks for two things: their incredible potential and their equally incredible volatility. Unfortunately, stakeholders of medical-cannabis producer Terra Tech (OTCMKTS:TRTC) find themselves in the latter category.So far this year, TRTC stock is down around 53%.And the bad news doesn't end there. Terra Tech only had $1.9 million of cash at the end of Q2.So why take a bet on TRTC stock? First, its vertically integrated organization may facilitate significant efficiencies as political momentum increases. Second, I dig their leadership team. The head execs are experts in finance, which should prove beneficial in properly navigating TRTC across choppy waters. Charlotte's Web (CWBHF)Source: Shutterstock When most people look at Charlotte's Web (OTCMKTS:CWBHF), they're thinking that they missed the boat. After all, CWBHF stock jumped 78% at the beginning of this year.From the opening price this year, however, Charlotte's Web shares are down over 10%.As much as I love marijuana stocks, I'm fairly certain that this cannabis firm is due for a further pullback. But once that occurs, I wouldn't waste too much time squabbling over the granularity.Instead, I'd consider what our own Matt McCall had to say. Thanks to the popularity of CBD, Charlotte's Web's CBD-based products could be distributed across mainstream retail channels. * 7 Retail Stocks to Avoid for the Holidays Unquestionably, such an event would launch CWBHF stock into the stratosphere. Moreover, because most CBD products contain no trace of THC, they don't fall under severe federal guidelines. Therefore, don't get too greedy looking for an ideal price point when CWBHF corrects. Cannabis Science (CBIS)On paper, Cannabis Science (OTCMKTS:CBIS) represents the next evolution among cannabis stocks: pharmaceutical firms that devote their time and research exclusively toward medical marijuana.Not only that, this is a much-needed development that could lift CBIS stock, as well as the entire botanical industry.For decades, people unquestionably trusted the mainstream healthcare and pharmaceutical network.However, the rapidly escalating opioid crisis has proven that well-intentioned medical professionals can lever a tragic impact. One of the underlying causes of this crisis is the addictiveness of prescribed medicines.Organizations like Cannabis Science can potentially mitigate this situation with naturally sourced therapies free of psychoactive side-effects. That's the allure of CBIS stock. However, shares trade for $0.0049 cents a pop, so this is only for the risk-tolerant. GW Pharmaceuticals (GWPH)Source: Shutterstock On a surface level, GW Pharmaceuticals (NASDAQ:GWPH) brings a lot of positives to the table. As pioneers among medicinally-concentrated marijuana stocks, they lever substantial credibility.Their Sativex drug for addressing symptoms associated with multiple sclerosis achieved better-than-expected results. This only encourages other companies to pursue cannabis-based therapies for many other diseases. * 7 Retail Stocks to Avoid for the Holidays As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks to Sell Before They Roll Over * 5 Beaten-Up Stocks to Buy That Could Be Saved By An Acquisition * 4 Startup Stocks Getting Smashed The post 10 Medical Marijuana Stocks to Cure Your Portfolio appeared first on InvestorPlace.

  • GlobeNewswire

    Emerald Health Therapeutics to Supply STENOCARE with Medical Cannabis Products for Denmark

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has signed an agreement to become a new supplier to STENOCARE A/S (“STENOCARE”) of medical cannabis for Denmark and STENOCARE’s international markets. STENOCARE and Emerald will now commence the work with the Danish Medicines Agency (“DMA”) to have Emerald’s products ready and approved for the Danish Medical Cannabis Pilot Programme. The companies are aiming for product approval for CBD oil, THC oil and CBD+THC oil.

  • GlobeNewswire

    Emerald Health Therapeutics to Participate in Cowen 2nd Annual Boston Cannabis Conference

    VANCOUVER, British Columbia, Oct. 31, 2019 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) will participate in the Cowen 2nd Annual Boston Cannabis.

  • GlobeNewswire

    Emerald Health Therapeutics Announces Internal Reorganization

    Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has announced an internal reorganization including the reduction of its workforce and other expenditures. It is at the same time reinforcing its commitment to new product development focused on enhancing the modulation of the body’s endocannabinoid system. “Although such decisions are difficult, we will evolve our strategy, structure, and capabilities as necessary to be able to capitalize on key trends in the changing cannabis sector,” said Dr. Avtar Dhillon, Executive Chairman of the Board and President of Emerald.

  • Benzinga

    Emerald Health Therapeutics Spearheads Innovation Of Craft Cannabis With Verdélite Sciences, Inc. Operation

    Thierry Schmidt, President of Verdélite Sciences, Inc. and Chief Commercial Officer of Emerald Health Therapeutics (TSXV: EMH) (OTCQX: EMHTF), spoke with Benzinga regarding Verdélite’s prospects as a now fully-licensed, vertically-integrated cannabis production and processing facility. About Emerald Health Therapeutics and Verdélite Sciences, Inc. Emerald Health Therapeutics is a licensed Canadian-based producer of cannabis products for medical and adult-use customers.

  • Benzinga

    These Were The Companies Added And Removed From OTC Markets Indexes At The End Of Q3

    Most major cap-weighted indexes are rebalanced quarterly, semi-annually, or annually. This rebalancing consists of adding and removing securities based on market cap fluctuations throughout the quarter.  ...

  • GlobeNewswire

    Emerald Health Therapeutics Expands Adult-Use Cannabis Product Distribution to Nova Scotia

    VANCOUVER, British Columbia, Oct. 22, 2019 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has fulfilled its first shipment of premium cannabis.

  • GlobeNewswire

    Emerald Health Therapeutics’ Québec Premium Cannabis Operation Receives Sale License Amendment, Allowing Direct Sales of Branded Products

    OTCQX: EMHTF) wholly-owned production facility, Verdélite, in St. Eustache, Québec, has received from Health Canada its license amendment permitting it to sell and distribute packaged, branded dried cannabis products directly to provincial/territorial wholesalers and authorized private retailers in accordance with provincial/territorial frameworks in Canada. To date, Verdélite has been packaging product under the Emerald brand.

  • GlobeNewswire

    Emerald Health Therapeutics’ Metro Vancouver Organic Cannabis Operation Receives Cultivation Expansion License for Total Growing Area in First Greenhouse

    OTCQX: EMHTF) has received from Health Canada its cultivation license amendment and has full municipal permitting for its first of two 78,000 square foot greenhouses at its organic Metro Vancouver site in British Columbia. With an additional 50,000 square feet and seven grow areas licensed for cultivation-related activities, Emerald can now begin commercial greenhouse production at this site. This second license amendment builds on the initial site license, received in June of this year, used to propagate premium organic plant stock for this site, as well as the first amendment, received in July of this year, which added 12 acres of outdoor cultivation area.

  • GlobeNewswire

    Emerald Health Therapeutics Announces Update On Pure Sunfarms Supply Agreement

    OTCQX: EMHTF) announced that it has notified Pure Sunfarms Corp. ( the “Joint Venture”), its 50%-owned joint venture, that it does not agree that Emerald has any liability under the current Supply Agreement between Emerald and the Joint Venture with respect to the Joint Venture’s recent sales of cannabis to third parties at prices below the predetermined purchase price to Emerald (the “Purchase Price”) set out in the Supply Agreement.

  • Newsfile

    Interview with Emerald Health Therapeutics - VP Bernie Hertel Talks Pure Sunfarms JV and Expanding Operations

    Toronto, Ontario--(Newsfile Corp. - October 11, 2019) - Capital 10X President Evan Veryard sits down with Emerald Health Therapeutics (TSXV: EMH) (OTCQX: EMHTF) VP of Finance and Communications Bernie Hertel.Cannot view this video? Visit:https://capital10x.com/interview-emerald-health-therapeutics-sunfarms-jv-expanding-operations/Mr. Hertel provides an overview of Emerald Health Therapeutics; a Canadian licensed producer of cannabis products led by a team of life science professionals. He details their "defined dose" approach to developing differentiated products for medical- and adult-use customers.This ...

  • GlobeNewswire

    Emerald Health Therapeutics’ Quebec Cannabis Operation Receives License Expansion for Total Facility Area

    OTCQX: EMHTF) wholly-owned cannabis production facility, Verdélite, in St. Eustache, Quebec, has received from Health Canada a license amendment for the complete growing and processing area in its 88,000 square foot indoor facility. The additional 50,000 square feet will allow Verdélite to expand production from 4 to 21 highly-controlled-environment grow rooms and to a total of 16 processing rooms. “Verdélite is now fully built and licensed across all its growing and processing areas, and I congratulate the team for this accomplishment,” said Thierry Schmidt, President of Verdélite.

  • GlobeNewswire

    Emerald Health Therapeutics’ Joint Venture Pure Sunfarms Begins Shipping Branded Cannabis Product to British Columbia Provincial Wholesaler

    OTCQX: EMHTF), today announced its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms Corp. ("Pure Sunfarms" or "PSF"), has begun shipping branded, packaged dried cannabis products to the British Columbia Liquor Distribution Branch (“BCLDB”), which acts as the provincial wholesaler of non-medical cannabis, supplying licensed private retailers and the government-run online store and stand-alone BC Cannabis Stores. Pure Sunfarms expects its first products to soon be available to retail customers in British Columbia. Pure Sunfarms began shipping product to the Ontario provincial wholesaler, the Ontario Cannabis Retail Corporation (the "OCRC", operating as the Ontario Cannabis Store), in September.  Combined, Ontario and British Columbia comprise more than half of Canada’s population.

  • GlobeNewswire

    Emerald Health Therapeutics’ Joint Venture Pure Sunfarms Launches Branded Product Line, Introducing Eight Products for the Recreational Market, and Begins Shipping to Ontario Cannabis Store

    OTCQX: EMHTF), today announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms (PSF), has formally launched its Pure Sunfarms branded products and introduced eight strains of dried cannabis flower for the Canadian recreational market. It has also begun shipping branded dried cannabis products to the Ontario Cannabis Store (“OCS”) for retail sale in Ontario.

  • GlobeNewswire

    Emerald Health Therapeutics to Participate at the Eight Capital & Cassels Brock Global Cannabis Conference

    VANCOUVER, British Columbia, Sept. 16, 2019 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF), today announced that it will participate in a panel and.